The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback